CRISPR Therapeutics
CRSP
257 hedge funds and large institutions have $1.51B invested in CRISPR Therapeutics in 2020 Q1 according to their latest regulatory filings, with 50 funds opening new positions, 97 increasing their positions, 54 reducing their positions, and 44 closing their positions.
80% more repeat investments, than reductions
Existing positions increased: 97 | Existing positions reduced: 54
30% more call options, than puts
Call options by funds: $41.5M | Put options by funds: $31.8M
14% more first-time investments, than exits
New positions opened: 50 | Existing positions closed: 44
5.14% more ownership
Funds ownership: 53.3% → 58.44% (+5.1%)
2% more funds holding
Funds holding: 253 → 257 (+4)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
22% less capital invested
Capital invested by funds: $1.92B → $1.51B (-$416M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$68.6M |
| 2 |
NAMA
Nikko Asset Management Americas
New York
|
+$37M |
| 3 |
Morgan Stanley
New York
|
+$30.8M |
| 4 |
TCM
TimesSquare Capital Management
New York
|
+$18.8M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
+$17.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$19.1M |
| 2 |
Millennium Management
New York
|
-$19M |
| 3 |
Two Sigma Investments
New York
|
-$11.9M |
| 4 |
O
OrbiMed
New York
|
-$11.1M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$9.49M |
CRSP Hedge Fund Activity: Q1 2020 in Review
257 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in CRISPR Therapeutics (CRSP) for Q1 2020, worth a combined $1.51B — down 22% from $1.92B a quarter earlier.
Buyers outnumbered sellers: 50 funds opened new CRSP positions and 44 closed out — a net gain of 6 holders — while 97 added to existing stakes and 54 trimmed.
The largest buyer was ARK Investment Management, adding an estimated $68.6M. The largest seller was Cormorant Asset Management, cutting an estimated $19.1M.
- 257 institutional investors held CRISPR Therapeutics (CRSP) as of Q1 2020, up from 253 in Q4 2019.
- Funds reported $1.51B of CRISPR Therapeutics stock for Q1 2020, down 22% quarter-over-quarter.
- 50 funds opened new CRISPR Therapeutics positions in Q1 2020 and 44 closed out, a net change of +6 holders.
- The largest CRISPR Therapeutics buyer in Q1 2020 was ARK Investment Management, an estimated $68.6M added.
- The largest CRISPR Therapeutics seller in Q1 2020 was Cormorant Asset Management, an estimated $19.1M sold.
Based on aggregated 13F filings for Q1 2020.